Oragenics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OGEN NYSE American 2830 www.oragenics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Oragenics, Inc.

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - Aug 28th, 2026 2:25 pm
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - Jul 7th, 2026 6:30 am
Sidoti Events, LLC's May Micro-Cap Virtual Conference - May 20th, 2026 5:30 am
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21 - May 19th, 2026 6:45 am
ORAGENICS PROVIDES INVESTOR UPDATE - May 18th, 2026 6:30 am
Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - May 7th, 2026 6:30 am
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - May 5th, 2026 6:30 am
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - Apr 20th, 2026 7:00 am
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - Apr 13th, 2026 6:30 am
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - Mar 25th, 2026 4:30 pm
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - Feb 9th, 2026 6:30 am
Oragenics partners with Duck Flats Pharma to support FDA IND trial design - Feb 4th, 2026 6:40 am